Login to Your Account

Shares Fall, Then Recover

Antibiotic Jitters Take Hold as Arpida Files Iclaprim NDA

By Cormac Sheridan

Thursday, March 20, 2008
Underlining both the general volatility in the wider public markets and the specific uncertainties attaching to the FDA's present treatment of new drug applications for antibiotics, Arpida AG hit a 52-week low on news that it had completed a regulatory filing for Iclaprim, a synthetic diaminopyrimidine in development for treating complicated skin and skin structure infections (cSSSI). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription